Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05172349
Other study ID # L-Visio-AMTRIX-TBF4
Secondary ID IDRCB
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date April 2022
Est. completion date September 2022

Study information

Verified date August 2022
Source TBF Genie Tissulaire
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this open, multicenter pilot trial is to assess the impact of the use of an amniotic membrane on the healing of a persistent epithelial lesion or of a corneal ulcer.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Male or female between 18 and 80 years old - Stage 2 (persistent epithelial lesion : LEP) or stage 3 (corneal ulcer) trophic ulcer affecting only one eye. Patient whose contralateral eye is affected by stage 1 neurotrophic keratitis may also be included - Two or more weeks old LEP or corneal ulcer refractory to one or more conventional nonsurgical therapies - Absence of objective evidence of improvement of the epithelial ulceration or corneal ulcer within 2 weeks prior to study inclusion - Failure of amniotic membrane treatment of the trophic ulcer: failure by absence of healing a few day after overlay treatment or 15 days after inlay grafting - Patient able to understand French language - Informed and consenting patient - Patient affiliated to a social security system or beneficiary of such a system Exclusion Criteria: - Pregnant or breastfeeding patient or without contraception for non-menopausal women - Active infectious ulcer - Preperforating ulcer or ulcer that has reached the posterior 1/3 of the storm - Allergy to Oxybuprocaine or Tetracaine eye drops, to ester type local anesthetics and to fluorescein - Current contact lens wear, including scleral lenses - NSAID eye drops and any drops containing preservatives - Antibiotic, anti-viral, anti-parasitic eye drops - Patients with identified causes of the ulcer for which medical treatment without preservatives or other healing treatment is beneficial - Ocular surgery for other pathology than the trophic ulcer in the 3 months preceding the inclusion in the study - Ophthalmologic pathology requiring daily eye drops - Monophtalmic patients - Persons deprived of liberty by a judicial or administrative decision - Adults who are subject to a legal protection measure or who are unable to express their consent

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
LV-Visio-AMTRIX
Chemically-treated, viro-inactivated, freeze-dried and irradiated allograft placed by the investigator during patients' hospital visit

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
TBF Genie Tissulaire

Outcome

Type Measure Description Time frame Safety issue
Primary Largest diameter of persistent epithelial lesion area or corneal ulcer under 0.5 mm Diameter assessed by centralized reading on photograph after fluorescein test 15 days
Secondary Recovery of the visual acuity evaluated by Monoyer chart 30 days, 45 days
Secondary Stable or decreased score for inflammatory and clinical signs of the ocular surface Composite score for inflammatory and clinical signs of the ocular surface on 66 points. Duration and intensity are evaluated for secretion, dry eyes, tearing, foreign body sensation, fluctuating vision, photophobia, burning sensation and lids edema. Duration is evaluated from a scale from 0: never to 4: all the time. Intensity is evaluated from a scale from 0: slight to 2: severe. Localization and intensity are evaluated for conjunctival edema, conjunctival redness and neovascularization. Localization is evaluated on a scale from 0: no reaction to 4: reaction present in the whole eye. 2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
Secondary Stabilisation or decrease of pain evaluated on visual analog scale VAS on 10 points from 0: no pain to 10: worst imaginable pain 2 days, 4 days, 7 days, 10 days, 15 days, 30 days, 45 days
See also
  Status Clinical Trial Phase
Recruiting NCT05705024 - Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells Phase 2
Completed NCT02731638 - Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers Phase 3
Completed NCT00324168 - Steroids for Corneal Ulcers Trial Phase 4
Completed NCT04484402 - Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells Phase 1/Phase 2
Completed NCT04820010 - Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3
Recruiting NCT02570321 - Cross-linking for Corneal Ulcers Treatment Trial Phase 4
Completed NCT00386958 - A Clinical Trial of Povidone-Iodine for the Treatment of Bacterial Corneal Ulcers Phase 2
Completed NCT04054817 - ACRO Biocornea Clinical Trial in Taiwan N/A
Completed NCT00997035 - The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo Phase 3
Completed NCT02277054 - Safety and Effectiveness of Collagen-phosphorylcholine Bioengineered Cornea in Patients Requiring Lamellar Keratoplasty N/A
Recruiting NCT05313828 - Effect of Various Treatment Modalities on Dendritic Vial Ulcer
Recruiting NCT05255016 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Refractory Corneal Ulcers Phase 2/Phase 3
Recruiting NCT05255107 - Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers Phase 2/Phase 3
Completed NCT05891106 - AONDA Therapeutic Indication Study I
Terminated NCT00789646 - Painless Subconjunctival Antibiotic and Antifungal Injection in Corneal Ulcer Patients N/A
Not yet recruiting NCT05940376 - Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
Completed NCT05200000 - Wharton's Jelly Eye Drops in the Treatment of Chronic Keratitis Phase 1
Completed NCT01756456 - Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis. Phase 1/Phase 2
Active, not recruiting NCT01969786 - Village Integrated Eye Workers Trial N/A
Completed NCT01794312 - Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer Phase 3